Outcomes of all patients after UCB transplantation based on the presence or absence of NK-cell alloreactivity in the GVHD direction
| Outcome . | Myeloablative conditioning . | Reduced-intensity conditioning . | ||||
|---|---|---|---|---|---|---|
| KIR-L mismatched, n = 41 . | KIR-L matched, n = 114 . | P . | KIR-L mismatched, n = 33 . | KIR-L matched, n = 69 . | P . | |
| Grade II-IV GVHD, % (95% CI) | 46 (30-64) | 46 (36-56) | .82 | 79 (59-99) | 57 (44-70) | .01 |
| Grade III-IV GVHD, % (95% CI) | 17 (6-28) | 17 (10-24) | .97 | 42 (27-59) | 13 (5-21) | < .01 |
| Chronic GVHD at 1 year, % (95% CI) | 10 (1-19) | 21 (13-29) | .16 | 12 (1-23) | 14 (6-22) | .91 |
| TRM at 2 years, % (95%CI) | 27 (14-40) | 18 (11-25) | .19 | 27 (12-42) | 12 (5-19) | .03 |
| Relapse at 2 years, % (95% CI) | 18 (6-30) | 28 (19-37) | .37 | 39 (21-57) | 47 (34-60) | .72 |
| Survival at 3 years, % (95% CI) | 50 (32-68) | 57 (47-67) | .46 | 32 (15-59) | 52 (47-67) | .03 |
| Outcome . | Myeloablative conditioning . | Reduced-intensity conditioning . | ||||
|---|---|---|---|---|---|---|
| KIR-L mismatched, n = 41 . | KIR-L matched, n = 114 . | P . | KIR-L mismatched, n = 33 . | KIR-L matched, n = 69 . | P . | |
| Grade II-IV GVHD, % (95% CI) | 46 (30-64) | 46 (36-56) | .82 | 79 (59-99) | 57 (44-70) | .01 |
| Grade III-IV GVHD, % (95% CI) | 17 (6-28) | 17 (10-24) | .97 | 42 (27-59) | 13 (5-21) | < .01 |
| Chronic GVHD at 1 year, % (95% CI) | 10 (1-19) | 21 (13-29) | .16 | 12 (1-23) | 14 (6-22) | .91 |
| TRM at 2 years, % (95%CI) | 27 (14-40) | 18 (11-25) | .19 | 27 (12-42) | 12 (5-19) | .03 |
| Relapse at 2 years, % (95% CI) | 18 (6-30) | 28 (19-37) | .37 | 39 (21-57) | 47 (34-60) | .72 |
| Survival at 3 years, % (95% CI) | 50 (32-68) | 57 (47-67) | .46 | 32 (15-59) | 52 (47-67) | .03 |
P values less than .05 are shown in bold for easy identification.
UCB indicates umbilical cord blood; NK, natural killer; GVHD, graft-versus-host disease; KIR-L, killer-cell immunoglobulin–like receptor ligand; and TRM, treatment-related mortality.